Childhood systemic lupus erythematosus, dermatomyositis, scleroderma, and systemic vasculitis.
Recent developments in the identification of prognostic features, measures of disease activity, and responses to therapy in the childhood rheumatic diseases are summarized. Progress in understanding the immunopathogenesis of neonatal lupus erythematosus phenomenon and Kawasaki disease is reviewed.
Ilowite
N T
NT
Division of Pediatric Rheumatology, Schneider Children's Hospital, New Hyde Park, NY 11042.
D000293:Adolescent; D017152:Antibodies, Antiphospholipid / Q000097:blood; D002648:Child; D003181:Complement C4 / Q000032:analysis; D003882:Dermatomyositis / Q000188:drug therapy / Q000276:immunology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007231:Infant, Newborn; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy / Q000276:immunology; D008947:Mixed Connective Tissue Disease / Q000188:drug therapy / Q000276:immunology; D009080:Mucocutaneous Lymph Node Syndrome / Q000188:drug therapy / Q000276:immunology; D010488:Polyarteritis Nodosa / Q000188:drug therapy / Q000276:immunology; D012595:Scleroderma, Systemic / Q000188:drug therapy / Q000276:immunology
D017152:Antibodies, Antiphospholipid; D003181:Complement C4; D007166:Immunosuppressive Agents